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Psoriasis is a prevalent, chronic systemic inflammatory 
skin disease, affecting approximately 2–3% of the gene-
ral population; more than 125 million people worldwide 
(1). While 6–40% of patients with psoriasis develop pso-
riasis arthritis (PsA), psoriasis has also been associated 
with a host of autoimmune diseases, including vitiligo, 
multiple sclerosis, rheumatoid arthritis and inflammatory 
bowel disease; partly explained by shared genetic risk 
variants (2–4). Recently, we conducted a nationwide 
cohort study in Denmark, and showed that the incidence 
rate ratio for autoimmune hepatitis was increased 2–3-
fold in persons with psoriasis (5). In 2012, Wu et al. (4), 
conducted a retrospective cohort study including 25,341 
individuals with psoriasis and/or PsA and showed that 
patients with psoriasis were more likely to have at least 2 
other autoimmune diseases compared with healthy con-
trols. Given the associations between psoriatic disease 
and a number of autoimmune conditions, an increased 
prevalence of psoriatic disease among members of the 
Danish National Addison’s Disease Advocacy group 
(unpublished observation), and the limited available 
data on the association between primary adrenal insuf-
ficiency (PAI) and psoriasis, we conducted a nationwide 
case-control study to examine a potential association 
between these conditions.
METHODS
Study approval was obtained from the Danish Data Protection 
Agency (ref. 2007-58-0015, int. ref. GEH-2014-018, I-Suite 
02736). Review by an ethics committee is not required for regis-
ter studies in Denmark. Conduct of this study was in accordance 
with the Strengthening the Reporting of Observational Studies in 
Epidemiology recommendations (6). 
The Danish National Health Service provides universal tax-
supported healthcare, guaranteeing unrestricted access to general 
practitioners and hospitals and partial reimbursement for pres-
cribed medications. Information on date of birth, sex, and date 
of death are available from the Civil Personal Register (7). The 
Danish National Patient Register contains data on admission and 
discharge dates and discharge diagnoses from all non-psychiatric 
hospitals since 1977 and on emergency room and outpatient clinic 
visits since 1995 (8). The International Classification of Diseases 
(ICD)-8 codes were used until the end of 1993. From 1994, the 
Danish adaptation of ICD-10 was implemented, whereas ICD-9 
was never used in Denmark. Statistics Denmark records informa-
tion on tax-reported household income (9). 
All Danish patients with a first-time hospital diagnosis of pri-
mary adrenal insufficiency (ICD-10 codes E27.1A and E27.2) 
between 1 January 1997 and 31 December 2012 were identified. 
Each case was matched on age, sex, and date of diagnosis with 5 
healthy controls. That is, control subjects had to be alive, resident 
in the source population, and at risk for first hospital admission for 
PAI at the time the corresponding case was diagnosed. We defined 
the index date of control subjects as the date of first PAI diagnosis 
for the corresponding case. Using this risk set sampling design, 
the case-control odds ratio (OR) provides an unbiased estimate of 
the corresponding incidence rate ratio. We identified all patients in 
this cohort with psoriasis and PsA. Patients were classified with 
severe disease when they received systemic anti-psoriatic therapy 
consistent with severe disease (biological drugs, cyclosporine, 
psoralens, retinoids, or methotrexate). We have previously descri-
bed and validated the method for identification of psoriasis, and 
classification of severity, with a sensitivity of 98% (10).
SAS version 9.4 (SAS Institute Inc. Cary, NC, USA) and STATA 
version 11.2 (StataCorp, College Station, TX, USA) were used to 
compute case-control ORs with 95% confidence intervals (95% 
CIs), based on conditional logistic regression (11). This model 
inherently adjusts for the matched factors, and we also adjusted 
the models for differences in socio-economic status and smoking 
history, respectively. Socio-economic status was calculated as an 
index between 0 and 4 based on the average gross annual income 
(standardized by age) during a 5-year period before the index date. 
A 2-tailed p-value < 0.05 was considered statistically significant.
RESULTS
The study population included 1,199 individuals with PAI 
and 5,995 matched control subjects between 1 January 
1997 and 31 December 2012 (65% women and mean 
age 52.8 years in both groups). Smoking was twice as 
common in PAI as in control subjects (15.4% vs. 7.8%, 
but the mean socioeconomic status was similar (1.9 vs. 
2.0). In individuals with PAI, the adjusted ORs were 1.28 
(0.83–1.96, p = 0.261) for any psoriasis (psoriasis regard-
less of severity) without PsA, 1.14 (0.38–3.44, p = 0.809) 
for severe psoriasis without PsA, 3.48 (1.54–7.81, 
p = 0.003) for PsA only, and 2.2 (1.07–4.52, p = 0.032) for 
severe psoriasis with or without PsA (Table I). When we 
examined the temporal relationship, i.e. whether psoriatic 
disease preceded PAI, or vice versa, fully adjusted ORs 
of pre-existing psoriasis were 1.64 (1.08–2.49, p = 0.021), 
whereas the OR of psoriasis onset after PAI was 1.22 
(0.53–2.83, p = 0.636), as shown in Table II.
DISCUSSION
In this population-based study, PAI was significantly as-
sociated with pre-existing PsA, but not psoriasis, when 
compared with matched controls. The explanation for 
the association is unclear, but a potential mechanistic 
link could be mediated by dysregulated tissue resident 
memory T cells (TRM), which reside long-term in pe-
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ripheral tissues (2). TRM probably evolved to supply 
epithelial barriers throughout the body with protective 
T cells with the ability to react to pathogens most rele-
vant in their respective tissues (12). TRM play a key role 
in the pathogenesis of psoriasis and other autoimmune 
conditions associated with psoriasis (12). Furthermore, 
autoimmune diseases share a large proportion of their 
genetic background and it has been shown that many 
diseases have more than 50% of their associated loci in 
common with another disease (2). This is further sup-
ported by the fact that the relative risk of developing an 
autoimmune disease is increased in children of patients 
with an autoimmune disease (13). Along this line, there 
are important genetic differences between psoriasis and 
PsA, which may explain the somewhat differing results 
observed in these two groups (14). 
Several strengths and limitations apply when inter-
preting the results of our study. Limitations include the 
observational nature of the study and possible influence 
of unknown confounders. While PAI is a rare disease, 
the population-based setting employed here enables 
analysis of a large number of individuals 
with complete follow-up. Since pre-existing 
psoriasis was not associated with an increased 
risk of PAI, surveillance bias is unlikely to 
have markedly influenced our results, and 
the exclusion of secondary adrenal insuffi-
ciency limited bias, e.g. due to treatment with 
systemic glucocorticoids. Also, nationwide 
databases allow us to analyse a large number 
of patients with minimal selection bias. The 
complete registration, the prospective nature 
of prescription data, the ICD diagnostic co-
des, and the use of validated information on 
exposure and outcome measures ensure that 
recall bias and bias caused by non-response 
are minimized. Although, the mechanisms 
underlying the relationship between PsA and 
PAI, as well as the potential clinical implications, remain 
to be established, these findings add to the growing body 
of evidence of comorbidities associated with PsA.
Disclosures: LS has received consultancy and/or speaker honoraria 
from Abbott, Pfizer, Janssen-Cilag, MSD, and Leo Pharma. LS is 
a member of the advisory boards of MSD, Novartis, Eli Lilly and 
Co., Abbvie, Celgene, Amgen, and Janssen-Cilag. PJ has received 
speaker honoraria from Abbvie, Pfizer, and Janssen-Cilag. AE 
has received research funding and/or consultancy honoraria from 
Pfizer, Eli Lilly and Co.
REFERENCES
1. Nestle FO, Kaplan DH, Barker J. Psoriasis. N Engl J Med 
2009; 361: 496–509. 
2. Zhernakova A, Withoff S, Wijmenga C. Clinical implications of 
shared genetics and pathogenesis in autoimmune diseases. 
Nat Rev Endocrinol 2013; 9: 646–659. 
3. Ogdie A, Weiss P. The epidemiology of psoriatic arthritis. 
Rheum Dis Clin North Am 2015; 41: 545–568.
4. Wu JJ, Nguyen TU, Poon K-YT, Herrinton LJ. The association 
of psoriasis with autoimmune diseases. J Am Acad Dermatol 
2012; 67: 924–930. 
5. Jensen P, Egeberg A, Gislason G, Hansen PR, Thyssen JP, 
Skov L. Increased risk of autoimmune hepatitis in patients 
with psoriasis: a Danish nationwide cohort study. J Invest 
Dermatol 2016; 136: 1515–1517. 
6. Vandenbroucke JP, von Elm E, Altman DG, Gøtzsche PC, 
Mulrow CD, Pocock SJ, et al. Strengthening the Reporting of 
Observational Studies in Epidemiology (STROBE): explana-
tion and elaboration. PLoS Med 2007; 4: e297.
7. Schmidt M, Pedersen L, Sørensen HT. The Danish Civil Re-
gistration System as a tool in epidemiology. Eur J Epidemiol 
2014; 29: 541–549. 
8. Andersen TF, Madsen M, Jørgensen J, Mellemkjoer L, Olsen 
JH. The Danish National Hospital Register. A valuable source 
of data for modern health sciences. Dan Med Bull 1999; 46: 
263–268.
9. Baadsgaard M, Quitzau J. Danish registers on personal in-
come and transfer payments. Scand J Public Health 2011; 
39: 103–105.
10. Egeberg A, Mallbris L, Gislason GH, Skov L, Hansen PR. Risk 
of multiple sclerosis in patients with psoriasis: a Danish na-
tionwide cohort study. J Invest Dermatol 2016; 136: 93–98.
11. Lachin JM. Sample size evaluation for a multiply matched 
case-control study using the score test from a conditional 
logistic (discrete Cox PH) regression model. Stat Med 2008; 
27: 2509–2523. 
12. Clark RA. Resident memory T cells in human health and 
Table II. Odds ratios (ORs) of psoriasis and psoriatic arthritis before/
after diagnosis of primary adrenal insufficiency (PAI)
Crude 
OR* 95% CI
p- 
value
Adj. 
OR** 95% CI
p- 
value
Any psoriasis
  Before PAI 1.69 1.12–2.57 0.013 1.64 1.08–2.49 0.021
  After PAI 1.10 0.48–2.52 0.827 1.22 0.53–2.83 0.636
Any psoriasis without psoriatic arthritis
  Before PAI 1.28 0.78–2.10 0.322 1.27 0.78–2.10 0.339
  After PAI 1.22 0.52–2.82 0.650 1.34 0.57–3.14 0.497
Severe psoriasis
  Before PAI 2.50 1.12–5.56 0.025 2.27 1.00–5.11 0.049
  After PAI 1.46 0.29–7.34 0.649 1.37 0.27–6.96 0.705
Severe psoriasis without psoriatic arthritis
  Before PAI 1.36 0.38–4.89 0.634 1.30 0.36–4.71 0.688
  After PAI 0.70 0.08–5.96 0.747 0.70 0.08–5.95 0.742
Psoriatic arthritis
  Before PAI 4.09 1.70–9.87 0.002 3.66 1.49–9.01 0.005
  After PAI 1.67 0.17–16.02 0.658 1.78 0.18–17.69 0.624
*When using conditional logistic regression, the ORs are inherently adjusted for 
matched factors. **Adjusted (Adj.) for the matched factors and socio-economic 
status. CI: confidence interval.
Table I. Odds ratios (ORs) associating primary adrenal insufficiency (PAI) with 
psoriasis or psoriatic arthritis
 
PAI
n (%)
Controls
n (%)
Crude 
OR* 95% CI
p- 
value
Adj. 
OR** 95% CI
p- 
value
Any psoriasis
  No 1,162 (96.9) 5,874 (98.0) Ref. Ref.
  Yes      37 (3.1)    121 (2.0) 1.54 1.06–2.23 0.023 1.55 1.06–2.24 0.022
Any psoriasis without psoriatic arthritis
  No 1,172 (97.7) 5,888 (98.2) Ref. Ref.
  Yes      27 (2.3)    107 (1.8) 1.27 0.83–1.94 0.278 1.28 0.83–1.96 0.261
Severe psoriasis
  No 1,188 (99.1) 5,970 (99.6) Ref. Ref.
  Yes      11 (0.9)      25 (0.4) 2.23 1.09–4.55 0.028 2.20 1.07–4.52 0.032
Severe psoriasis without psoriatic arthritis
  No 1,195 (99.7) 5,977 (99.7) Ref. Ref.
  Yes        4 (0.3)      18 (0.3) 1.11 0.37–3.36 0.847 1.14 0.38–3.44 0.809
Psoriatic arthritis
  No 1,189 (99.2) 5,981 (99.8) Ref. Ref.
  Yes      10 (0.8)      14 (0.2) 3.57 1.59–8.04 0.002 3.48 1.54–7.81 0.003
*When using conditional logistic regression, the ORs are inherently adjusted for matched factors. 
**Adjusted (Adj.) for the matched factors and socio-economic status. CI: confidence interval.
A
ct
aD
V
A
ct
aD
V
A
d
v
a
n
c
e
s 
in
 d
e
rm
a
to
lo
g
y
 a
n
d
 v
e
n
e
re
o
lo
g
y
A
c
ta
 D
e
rm
a
to
-V
e
n
e
re
o
lo
g
ic
a
521Short communication
Acta Derm Venereol 2017
disease. Sci Transl Med 2015; 7: 269rv1.
13. Hemminki K, Li X, Sundquist K, Sundquist J. Shared fami-
lial aggregation of susceptibility to autoimmune diseases. 
Arthritis Rheum 2009; 60: 2845–2847.
14. Stuart PE, Nair RP, Tsoi LC, Tejasvi T, Das S, Kang HM, et 
al. Genome-wide association analysis of psoriatic arthritis 
and cutaneous psoriasis reveals differences in their genetic 
architecture. Am J Hum Genet 2015; 97: 816–836.
